Nephros (OTCMKTS:NEPH) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Nephros (OTCMKTS:NEPH) from a hold rating to a buy rating in a research note issued to investors on Tuesday, Zacks.com reports. They currently have $7.75 price target on the stock.

According to Zacks, “Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. “

Separately, Taglich Brothers restated a speculative buy rating on shares of Nephros in a research note on Wednesday, April 24th.

Shares of NEPH stock opened at $6.85 on Tuesday. The company has a quick ratio of 1.86, a current ratio of 2.56 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average of $5.49 and a two-hundred day moving average of $1.79. Nephros has a 52 week low of $3.69 and a 52 week high of $7.15. The company has a market cap of $52.56 million, a P/E ratio of -12.69 and a beta of 0.85.

In other news, insider Daron Evans bought 43,172 shares of the business’s stock in a transaction on Friday, June 14th. The stock was purchased at an average cost of $0.60 per share, for a total transaction of $25,903.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders acquired 81,672 shares of company stock valued at $72,598 over the last 90 days. 6.80% of the stock is currently owned by insiders.

About Nephros

Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Further Reading: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on Nephros (NEPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.